Get the Stockscreener App
161.15
1.15%
-1.87
Pre-market:
164.09
2.94
+1.82%
Natera Inc stock is traded at $161.15, with a volume of 1.49M.
It is down -1.15% in the last 24 hours and up +16.02% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$163.02
Open:
$164.74
24h Volume:
1.49M
Relative Volume:
1.10
Market Cap:
$22.12B
Revenue:
$1.96B
Net Income/Loss:
$-253.24M
P/E Ratio:
-84.37
EPS:
-1.91
Net Cash Flow:
$94.06M
1W Performance:
+2.62%
1M Performance:
+16.02%
6M Performance:
-4.86%
1Y Performance:
+29.98%
1-Day Range:
$160.94
$165.28
1-Week Range:
$152.62
$165.28
52-Week Range:
$110.57
$183.00
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
161.15 | 22.37B | 1.96B | -253.24M | 94.06M | -1.91 |
|
TMO
Thermo Fisher Scientific Inc
|
487.54 | 184.66B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
209.01 | 151.04B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
637.86 | 52.07B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
118.15 | 33.86B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
192.54 | 32.49B | 15.70B | 1.24B | 2.01B | 6.91 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Natera pursues ctDNA assay approval after Phase III victory - Clinical Trials Arena
Natera’s bladder cancer test shows survival benefits in phase III trial By Investing.com - Investing.com South Africa
Natera’s bladder cancer test shows survival benefits in phase III trial - Investing.com Canada
98% 18-Month Survival Rate: Natera's Breakthrough Bladder Cancer Test Proves Critical for Immunotherapy Success - Stock Titan
Natera (NTRA) Is Up 7.3% After Raising 2025 Revenue Guidance and Launching Fetal Focus Test Has The Bull Case Changed? - ca.finance.yahoo.com
Natera (NTRA) Is Up 7.3% After Launching Fetal Focus and Raising 2025 Revenue Guidance - simplywall.st
What is Natera Inc. s revenue forecastQuarterly Portfolio Summary & Weekly Top Stock Performers List - thegnnews.com
Natera president sells $136k in stock By Investing.com - Investing.com Nigeria
Natera: President Fesko sells $105k in shares By Investing.com - Investing.com Canada
Natera president sells $136k in stock - Investing.com India
Natera: President Fesko sells $105k in shares - Investing.com
Natera Surges 2.89% on $240M Volume as Institutional Buyers Pile In Stock Ranks 423rd in Market Activity Amid Analyst Upgrades - AInvest
LabCorp Fails to Block Natera Patent-Invalidity Claims Pre-Trial - Bloomberg Law News
Live Scanner Shows Breakout on Natera Inc.Big Profit Small Risk Alerts - beatles.ru
Can Natera Inc. Regain Momentum After Breakdown2025 Winners & Losers & Advanced Technical Analysis Signals - beatles.ru
Natera’s Strong Growth Potential and Market Leadership Justify Buy Rating - TipRanks
Natera Inc. Pullback Analyzed — Is It Time to ExitJuly 2025 EndofMonth & Fast Entry Momentum Trade Alerts - sundaytimes.kr
Non-invasive Prenatal Testing Market Set to Witness Massive - openPR.com
Natera price target raised to $195 from $185 at Morgan Stanley - MSN
5 Revealing Analyst Questions From Natera’s Q2 Earnings Call - Yahoo Finance
Compared to Estimates, Natera (NTRA) Q2 Earnings: A Look at Key Metrics - MSN
Natera (NTRA) Q2 Results: 32% Revenue Growth, Strong Buy RatingNews and Statistics - IndexBox
Natera Q2 Earnings Call Highlights Strong Growth, Raises Revenue Guidance and Announces New Product Launches and Innovations - AInvest
1 ‘Strong Buy’ Stock Analysts Think Will Soar 62% - Yahoo Finance
Natera (NTRA) Is Up 14.1% After Raising Revenue Guidance and Launching New Prenatal Test – Has the Bull Case Changed? - simplywall.st
Natera Insider Sold Shares Worth $958,059, According to a Recent SEC Filing - MarketScreener
Natera director Sheena Jonathan sells $958k in NTRA stock - Investing.com
Natera director Sheena Jonathan sells $958k in NTRA stock By Investing.com - Investing.com Australia
Natera Inc. Reports Strong Growth and Strategic Advances - TipRanks
Natera at Canaccord Conference: Growth and Innovation in Focus - Investing.com
Natera at Canaccord Conference: Growth and Innovation in Focus By Investing.com - Investing.com Australia
Natera Surges 1.76% on $290M Volume, Climbs to 356th in Market Activity - AInvest
How clinicogenomic data are reshaping kidney disease trials and drug discovery - Nature
New noninvasive prenatal test can screen for CF, other genetic diseases - Cystic Fibrosis News Today
Leerink Partners Maintains Natera(NTRA.US) With Buy Rating, Announces Target Price $235 - 富途牛牛
NTRA Q2 Deep Dive: Oncology Growth, Product Innovation, and Margin Pressures - TradingView
Natera Surges 3.35% as Daily Volume Slumps 49.12% to 310M Dollar Ranking 335th in Market Activity - AInvest
Natera Stock Jumps 13.69% In 3 Days As Technicals Signal Bullish Reversal - AInvest
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cytek Biosciences (CTKB), Natera (NTRA) and Warby Parker (WRBY) - The Globe and Mail
Natera: Piper Sandler Raises PT to $220 from $210, Maintains Overweight - AInvest
Natera And 2 Other Stocks That May Be Priced Below Their Estimated Value - Yahoo Finance
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates - MSN
Mixed Analyst Opinions on Healthcare Stocks Cytek Biosciences, Natera, and Warby Parker - AInvest
Natera introduces prenatal test for detecting inherited conditions - MSN
Natera raises revenue guidance to $2.1B and targets margin expansion through AI-driven efficiencies - MSN
Evercore Gives Natera (NTRA) Outperform Rating - MSN
Natera's Signatera test to be covered under Medicare - MSN
How much upside does Natera Inc. haveAnalyst Upgrade Watch - thegnnews.com
What is the Moat Score of Natera Inc.Free Growth Stock Screener - mustnews.co.kr
Natera Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Natera, Inc. (NASDAQ:NTRA) Q2 2025 Earnings Call Transcript - Insider Monkey
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Natera Inc Stock (NTRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Fesko John | PRESIDENT, CHIEF BUS. OFFICER |
Aug 14 '25 |
Sale |
155.46 |
678 |
105,401 |
152,747 |
| Sheena Jonathan | CO-FOUNDER |
Aug 08 '25 |
Sale |
161.90 |
3,070 |
497,047 |
242,252 |
| Sheena Jonathan | CO-FOUNDER |
Aug 11 '25 |
Sale |
153.67 |
3,000 |
461,012 |
34,282 |
| Chapman Steven Leonard | CEO AND PRESIDENT |
Aug 01 '25 |
Sale |
132.88 |
5,807 |
771,656 |
163,593 |
| Marcus Gail Boxer | Director |
Aug 01 '25 |
Sale |
133.17 |
2,496 |
332,395 |
5,763 |
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS |
Aug 01 '25 |
Sale |
132.89 |
3,000 |
398,657 |
123,059 |
0.04%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):